Concepedia

Author

Michael Entzeroth

University of Applied Sciences Biberach

Also Known As

M Entzeroth, M. ENTZEROTH, M. Entzeroth, Michael Entzeroth

78

Publications

3.6K

Citations

31

H-Index

60

Concepts

All Affiliations

University of Applied Sciences BiberachPharmazeutische Fabrik Dr. Reckeweg (Germany)University of Hawaii SystemETH ZurichBoehringer Ingelheim (Germany)
ME

About

Michael Entzeroth is an author at University of Applied Sciences Biberach specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

22

24

1.6K

2

Biochemistry

11

12

632

3

Natural Sciences

9

9

496

4

Engineering

1

1

12

5

Allergy

1

1

40

Michael Entzeroth

×

39

Publications

3.1K

Citations

29

H-Index

YearCitations

Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist

Henri Doods, Gerhard Hallermayer, Dongmei Wu,

British Journal of Pharmacology

2000

467

The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagonist: BIBP3226

K Rudolf, Wolfgang Eberlein, Wolfhard Engel,

European Journal of Pharmacology

1994

374

Function of the SIRT1 protein deacetylase in cancer

Walter Stünkel, Bee Keow Peh, Yong Tan,

Biotechnology Journal

2007

232

6-Substituted benzimidazoles as new nonpeptide angiotensin II receptor antagonists: synthesis, biological activity, and structure-activity relationships

Uwe J. Ries, Gerhard Mihm, Berthold Narr,

Journal of Medicinal Chemistry

1993

199

Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277

Wolfgang Wienen, Norbert Hauel, J. C. A. van Meel,

British Journal of Pharmacology

1993

192

SIRT1 Modulating Compounds from High-Throughput Screening as Anti-Inflammatory and Insulin-Sensitizing Agents

Vasantha M. Nayagam, Xukun Wang, Yong Tan,

SLAS DISCOVERY

2006

147

Pharmacological characterization of the selective nonpeptide neuropeptide Y Y1 receptor antagonist BIBP 3226.

Henri Doods, Wolfgang Wienen, Michael Entzeroth,

Journal of Pharmacology and Experimental Therapeutics

1995

127

Overview of High‐Throughput Screening

Michael Entzeroth, Horst Flotow, Peter Condron

Current Protocols in Pharmacology

2009

88

Adrenomedullin mediates vasodilation via CGRP1 receptors

Michael Entzeroth, Henri Doods, H. Wieland,

Life Sciences

1994

85

Subtype selectivity and antagonistic profile of the nonpeptide Y1 receptor antagonist BIBP 3226.

H. Wieland, Klaus‐Dieter Willim, Michael Entzeroth,

Journal of Pharmacology and Experimental Therapeutics

1995

84

Page 1